Evidence map›Paper›PMID 24949866›Full record

ArticleJournal of psychiatry & neuroscience : JPN2014

Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.

Natalie Matosin, Francesca Fernandez-Enright, Elisabeth Frank, Chao Deng, Jenny Wong, Xu-Feng Huang, Kelly A Newell

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  17. The Role of Metabotropic Glutamate Receptors in Social Behavior in Rodents.International journal of molecular sciences · 2019
    Review
  18. Current Concepts and Treatments of Schizophrenia.Molecules (Basel, Switzerland) · 2018
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Natalie MatosinThe Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, and Schizophrenia Research Institute, Sydney, New South Wales, Australia.
Francesca Fernandez-EnrightThe Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Schizophrenia Research Institute, Sydney, New South Wales, and School of Psychology, Faculty of Social Science, University of Wollongong, New South Wales, Australia.
Elisabeth FrankThe Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, and Schizophrenia Research Institute, Sydney, New South Wales, Australia.
Chao DengThe Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, and Schizophrenia Research Institute, Sydney, New South Wales, Australia.
Jenny WongThe Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, and Illawarra Health and Medical Research Institute, Wollongong, New South Wales, Australia.
Xu-Feng HuangThe Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, and Schizophrenia Research Institute, Sydney, New South Wales, Australia.
Kelly A NewellThe Faculty of Science, Medicine and Health, University of Wollongong, New South Wales, Illawarra Health and Medical Research Institute, Wollongong, New South Wales, and Schizophrenia Research Institute, Sydney, New South Wales, Australia.
Illawarra Health and Medical Research Institute · AUSchizophrenia Research Institute · AUUniversity of Wollongong · AU

Funding

Brain Tissue Resource Centre for Alcohol ResearchR28AA012725 · NIAAA · UNIVERSITY OF SYDNEY · PI Greg Trevor Sutherland · 2012 to 2026
$7.0M
NIAAA NIH HHS R28 AA012725
6 · The paper itself

Abstract

backgroundMetabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic targets for major depression (MD), bipolar disorder (BD) and schizophrenia. We aimed to determine whether mGluR2/3 and mGluR5 binding in the anterior cingulate cortex (ACC), a brain region essential for the regulation of mood, cognition and emotion, were differentially altered in these pathologies.

methodsUsing postmortem human brains derived from 2 cohorts, [(3)H]LY341495 binding to mGluR2/3 and [(3)H]MPEP binding to mGluR5 were measured by receptor autoradiography in the ACC. The first cohort comprised samples from individuals who had MD with psychosis (MDP), MD without psychosis (MDNP) and matched controls (n = 11-12 per group). The second cohort comprised samples from individuals who had MDNP, BD, schizophrenia and matched controls (n = 15 per group).

resultsNo differences in mGluR2/3 or mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control group (all p > 0.05). Importantly, there were also no differences in binding densities between the psychiatric disorders (p > 0.05). We did, however, observe age-related effects, with consistent negative associations between mGluR2/3 and age in the control group (r < -0.575, p < 0.025) and the psychotic disorder groups (MDP and schizophrenia: r = -0.765 to -0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD). LIMITATIONS: Replication in larger independent cohorts and medication-naive individuals would strengthen these findings.

conclusionOur findings suggest that mGluRs are unaltered in the ACC; however, the presence of altered receptor function cannot be discounted and requires further investigation. Taken together with previous studies, which report differential changes in mGluR2, 3 and 5 across these disorders, we suggest mGluRs may be affected in a brain region-specific manner.

Indexed as

AdultAgingAutoradiographyBipolar DisorderCohort StudiesFemaleGyrus CinguliHumansMajor Depressive DisorderMaleMiddle AgedPsychotic DisordersReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateSchizophreniaYoung AdultGRM5 protein, humanmetabotropic glutamate receptor 2metabotropic glutamate receptor 3Receptor, Metabotropic Glutamate 5Receptors, Metabotropic Glutamate

Identifiers

PMID24949866
PMCPMC4214875
OpenAlexW2101159973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.